Raffles Medical Group (SGX:BSL) Stock Stalls Despite Firmer Profit Margins

Raffles Medical Group stock has been treading water, down about 4% over the past week and about 10% over three months, even as the latest results land. The headline from this earnings release is not the top line; it is profit quality. Net profit margin over the last twelve months sits at 9.1% compared with 8.3% a year ago, and earnings over that period are higher by about 5.9%.

For short term traders, the muted share price is the story. For long term investors, the real question is whether this margin improvement can stick over the coming years.

Love Raffles Medical Group's improving profit margin but concerned that the share price is still treading water? Compare it with list of solid balance sheet and fundamentals stocks (416 results).

H1 2026 Earnings Summary

• Revenue (H1 2026 vs H1 2025): S$353.19m vs S$378.45m (decline of 6.7%)
• Net Income, excluding extra items (H1 2026 vs H1 2025): S$29.02m vs S$32.11m (decline of 9.6%)
• Basic EPS (H1 2026 vs H1 2025): S$0.01577 vs S$0.01732 (decline of 9.0%)
• Net Profit Margin, trailing 12 months (latest vs prior year): 9.1% vs 8.3% (improvement of 0.8 percentage points)

Prefer clear visuals instead of another wall of earnings tables and margin figures? See Raffles Medical Group's full financial picture, including a visual breakdown of its profitability and margins, in the latest company report for Raffles Medical Group.

Raffles Medical’s margins support a cautious bullish tilt

For investors leaning positive on Raffles Medical Group, the latest figures offer some support. Revenue for H1 2026 is lower year on year, yet the trailing 12 month net profit margin has edged up to 9.1% from 8.3%. That points to some early success in tightening costs or mix, which fits a steady healthcare platform story rather than a pure growth push. Recent moves in neurology imaging and corporate governance also fit a business focused on clinical quality and operational discipline, themes that can matter more than headline growth for defensive healthcare stocks.

Earnings drift and muted price action feed the bear case

On the cautious side, the H1 2026 numbers give bears something to point to. Revenue is down 6.7%, with net income and basic EPS also lower compared with H1 2025. The share price has declined over 7 days, 30 days and 90 days, which suggests the market is yet to reward the margin uplift. For readers worried about execution across multiple countries and segments, this combination of softer top line and subdued market reaction will keep questions alive about how quickly Raffles Medical Group can translate its healthcare platform into stronger growth.

Compare the margin story at Raffles Medical Group with what the street is signaling on SGX:BSL. See the consensus price target analysis for Raffles Medical Group to check whether analysts think this earnings profile supports the current share price or points to a different path.

Stay Ahead With Simply Wall St

If you find Raffles Medical Group's improving profit margin and muted share price intriguing, register for free with Simply Wall St and add it to a Watchlist so you can track its share price against fair value and decide on an entry point that fits your plan. After you own it, use the Portfolio Command Center to cut through market noise and focus on the updates that matter most to your holdings. For a broader view, tap into crowd insights and different angles on Raffles Medical Group through the Community. This way you can monitor potential catalysts and risks early and stay a step ahead.

Seeking Fresh Alternatives Beyond Raffles Medical Group

Fresh ideas can move before anyone notices. Some stocks are building breakout momentum while they are still under the radar for now. Do not get caught watching. Consider acting based on your own research and judgment.

• Spot companies quietly building strength before momentum headlines hit by scanning the curated 305 resilient stocks with low risk scores while the risk reward trade off still looks balanced.
• Explore potential infrastructure and electrification themes early by checking hand picked 8 top copper producer stocks that could benefit if demand stays firm and capital keeps flowing.
• Focus on the intersection of healthcare and AI where real revenue matters by tracking carefully filtered 127 healthcare AI stocks before the crowd chases the story.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com